Soligenix, Inc. Common Stock
SNGX
SNGX: Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
moreShow SNGX Financials
Recent trades of SNGX by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by SNGX's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Compositions and methods of manufacturing trivalent filovirus vaccines Sep. 06, 2022
-
Patent Title: Peptides and analogs for use in the treatment of oral mucositis Apr. 26, 2022
-
Patent Title: Systems and methods for producing synthetic hypericin Jan. 07, 2020
-
Patent Title: Multivalent stable vaccine composition and methods of making same May. 21, 2019
-
Patent Title: Peptides and analogs for use in the treatment of oral mucositis Apr. 09, 2019
-
Patent Title: Systems and methods for producing synthetic hypericin Aug. 21, 2018
-
Patent Title: Peptides and analogs for use in the treatment of oral mucositis Dec. 26, 2017
-
Patent Title: Topically active steroids for use in interstitial pulmonary fibrosis Sep. 19, 2017
-
Patent Title: Peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity Aug. 16, 2016
-
Patent Title: Topically active steroids for use in interstitial pulmonary fibrosis Oct. 27, 2015
-
Patent Title: Peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity Jul. 29, 2014
-
Patent Title: Stabilized reverse micelle compositions and uses thereof Sep. 17, 2013
-
Patent Title: Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids Sep. 11, 2012
Federal grants, loans, and purchases
Followers on SNGX's company Twitter account
Number of mentions of SNGX in WallStreetBets Daily Discussion
Recent insights relating to SNGX
Recent picks made for SNGX stock on CNBC
ETFs with the largest estimated holdings in SNGX
Flights by private jets registered to SNGX